TP53 and prostate cancer: In contrast, treatment of these prostate cancer cells with SK1 selective (PF-543) or SK2 selective (ROMe) inhibitors alone or siRNA knockdown of SK1 or SK2 or their combination failed to induce an increase in the expression of p53 and p21.